Cyprotex
Website:  http://www.cyprotex.com

Cyprotex specialises in preclinical ADME Tox, both in vitro (laboratory experiments) and in silico (computer modelling). Cyprotex was founded in 1999, and in 2002 it was listed on the London Stock Exchange’s AIM Market (symbol CRX, information for investors). Our headquarters are in Macclesfield, UK, near Manchester.

Cyprotex serves all types and sizes of drug-discovery organisations, from the largest pharmaceutical companies to the smallest virtual companies, as well as academic and not-for-profit laboratories. We also support the research efforts of the cosmetic and agrochemical industries, principally for in vitro toxicity testing. Over 600 organisations trust Cyprotex for their ADME Tox research needs.

In 2010 Cyprotex acquired Apredica, a US-based pioneer in predictive toxicology and customised ADME research.